Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 7.83% from the previous trading day, before settling in for the closing price of $2.17. Within the past 52 weeks, ESPR’s price has moved between $1.58 and $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 9.55% annually for the last half of the decade. The company achieved an average annual earnings per share of 85.06%. With a float of $195.08 million, this company’s outstanding shares have now reached $195.44 million.
In an organization with 240 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc is 0.99%, while institutional ownership is 65.87%. The most recent insider transaction that took place on Dec 17 ’24, was worth 7,866. In this transaction Chief Financial Officer of this company sold 3,245 shares at a rate of $2.42, taking the stock ownership to the 240,691 shares. Before that another transaction happened on Dec 17 ’24, when Company’s Chief Commercial Officer sold 2,234 for $2.43, making the entire transaction worth $5,426. This insider now owns 160,121 shares in total.
Esperion Therapeutics Inc (ESPR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 85.06% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 4.57 million. That was better than the volume of 4.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.70%. Additionally, its Average True Range was 0.21.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 32.20%, which indicates a significant decrease from 92.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.02% in the past 14 days, which was lower than the 89.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.44, while its 200-day Moving Average is $2.24. However, in the short run, Esperion Therapeutics Inc’s stock first resistance to watch stands at $2.42. Second resistance stands at $2.50. The third major resistance level sits at $2.65. If the price goes on to break the first support level at $2.19, it is likely to go to the next support level at $2.04. The third support level lies at $1.96 if the price breaches the second support level.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 461.06 million based on 197,035K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 51,630 K in profit during its latest quarter, and -29,520 K in sales during its previous quarter.
